Navigation Links
Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
Date:5/16/2011

one as we execute on our clinical and pre-commercial strategies."

Key findings from this study include:

  • The study met its primary endpoint with a statistically significant reduction in cumulative pain score in patients receiving EXPAREL compared to placebo (p<0.0001).
  • A total of 189 patients were treated at 12 clinical sites in Europe.
  • The percentage of patients who were entirely opioid free was higher (p<0.0008) with EXPAREL than with placebo.
  • The median time to first opioid rescue was 14 hours and 20 minutes in the EXPAREL group, more than 10 times longer than the placebo group (1 hour and 10 minutes) (p<0.0001).
  • EXPAREL patients consumed statistically significantly less opioid rescue medication through 72 hours compared to the placebo group (p=0.0006).

In addition, the study showed that EXPAREL was well tolerated, with the incidence of adverse events (AEs) similar to placebo. GI side effects, commonly associated with opioid use, were reduced in the EXPAREL group compared to placebo, and there were no serious adverse events (SAEs) reported in patients receiving EXPAREL. Overall, 94.7% of patients treated with EXPAREL were "satisfied" or "extremely satisfied" with their postsurgical analgesia at 72 hours compared with 73.9% in the placebo group (p<0.0007).

There were no deaths or withdrawals due to an AE in the study.  There was one SAE (mild thrombophlebitis), which occurred in a patient who had received placebo, and was resolved the next day after treatment. The most common AEs experienced were gastrointestinal in nature, occurring in 8.4% of EXPAREL patients and 13.8% of placebo patients. 

For more information or to view the full poster, please visit the scientific presentations page located in the investors and media section on the Pacira website at www.pacira.com.

About Pacira'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
2. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
3. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
4. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
5. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
6. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
7. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
8. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
9. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
10. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
11. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) ... Stars Outlook 2015" report to their offering. ... sought after with fresh vigor as new targets , ... poised to bring a paradigm change in the way ... Stem cell therapy/Regenerative Medicine space. The number ...
(Date:3/5/2015)... 5, 2015 According to a ... Product (Systems and Disposables), by Type (Invasive, Minimally Invasive, ... and Ambulatory Sites) - Analysis & Global Forecast to ... expected to reach $1,107.4 Million by 2019 from $887.8 ... a CAGR of 4.5% during the forecast period. ...
(Date:3/5/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Therapeutic Drug Monitoring - ... This report deals with therapeutic ... improving patient care by monitoring drug levels in ... drugs for improving outcome. TDM is viewed as ...
Breaking Medicine Technology:Global Pharma Rising Stars Outlook 2015 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4Global Therapeutic Drug Monitoring Report 2015 - Technologies, Markets, and Companies Analysis 2014-2024 2
... 2011 - Bayer HealthCare Pharmaceuticals has become aware of a ... and swabsticks manufactured by the Triad Group and marketed under ... wants to ensure that U.S. patients and physicians using Bayer,s ... The recall of the Triad Group alcohol prep products ...
... U.S. Food and Drug Administration today approved Abstral (fentanyl) ... cancer.  Fentanyl immediate-release transmucosal medications are administered on the ... gums, tongue), or the nasal passages or throat where ...   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) "This is an ...
Cached Medicine Technology:Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 2Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 3FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain 2FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain 3
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , a ... repair market, reported record revenue of $4.79 million for ... $2.98 million in the year-ago fourth quarter demonstrating the ... “Our strong fourth quarter revenue growth reflects the market’s ... is driving increased surgeon adoption of our unique product ...
(Date:3/5/2015)... March 05, 2015 HomeCEUConnection.com ... March with extra savings on their nutrition ... of health and nutrition, HomeCEUConnection.com is offering ... the promo code, NUTRITION2015 . , ... , HomeCEUConnection.com provides high-quality continuing education ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 TCS Healthcare ... solutions for the population health management arena, is pleased ... case management software, ACUITY Advanced Care™ (ACUITY) version 7.20. ... improved performance and the advantages of automation. , The ... ET, will be led by Jeff Frater, RN, BSN, ...
(Date:3/5/2015)... 2015 University of Western States ... 1904, has launched a new center of excellence ... The Northwest Center for Lifestyle and Functional Medicine ... outreach, and conduct research in the areas of ... nutrition. The center will target efforts on the ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 INTEGRATED ... healthcare organizations to participate in its 2015 Children’s ... from executive and director-level positions, and the survey ... Last year’s report featured data on 60 executive ... children’s healthcare organizations and 7 subsidiary children’s hospitals. ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2
... those who have been hospitalized, risk may double over 7 ... Certain depressed patients who suffer from heart disease have nearly ... with other depressed patients, researchers say. , The patients ... severe depression within a few weeks of being hospitalized for ...
... of Tropical Medicine (LSTM) and Liverpool Associates in Tropical ... UK,s Department for International Development (DFID) to set up ... The IHLC will act as a ,one-stop-shop, source ... developers of links and those wishing to strengthen existing ...
... complications seen with ,after-hours, procedures, study finds , MONDAY, ... slot to undergo an orthopedic procedure may lower your ... new study has found. , The study, published ... Bone and Joint Surgery , found little difference otherwise ...
... Regurin(R) XL (trospium chloride), a,once-daily, prolonged-release capsule to ... the UK. Regurin(R) XL provides rapid,significant and consistent improvements ... for central nervous system (CNS) side effects(2-7). , ... is a condition that results from,sudden, involuntary contraction of ...
... ... supplier of medical devices, today announced FDA clearance of new RT50 wireless stimulator modules ... stimulation (FES) motorized ergometer system. , ... Baltimore, MD(PRWEB) September 5, 2009 -- Restorative Therapies, Inc., a designer ...
... , , ... Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research ... breakthrough stem cell and related technology. The Jordanian Stem Cell ... the technology from Stemedica,s wholly-owned subsidiary, Stemedica International, S.A. The ...
Cached Medicine News:Health News:Severe, Lasting Depression Tied to Heart Patient Deaths 2Health News:Creation of international health links center 2Health News:Let Orthopedic Surgery Wait Until Morning When Possible 2Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 2Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 3Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 4Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 5Health News:Restorative Therapies, Inc., Receives FDA Clearance for RT300 Enhancements 2Health News:Restorative Therapies, Inc., Receives FDA Clearance for RT300 Enhancements 3Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 3
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: